

# Blood Substitutes

*Where are we now??*

Anthony Dragovich MD  
Anesthesia Resident  
Uniformed Services  
University  
Bethesda, MD

What am I talking about?

Hemoglobin and Hemoglobin  
Substitutes

# Goals

- Explain why we need this
- Review hemoglobin physiology
- Detail the history of blood substitutes
- Discuss current hemoglobin based oxygen carriers



monet eXtreme4 painting by DIRRR  
monetextreme4.blogspot.com Nov 2004



# Why is this needed??

## *Limitations of heterologous blood*

- Limited availability of blood
- Compatibility issues
- Storage limitations
- Disease Transmission
- Immunomodulation

# Case Report—Denver Health Medical Center

- 18 yo male GSW to abdomen 30.06  
220 grain hollow point bullet
- Transfused 10 units Polyheme during  
1<sup>st</sup> 14 minutes of resuscitation
- Polyheme represented 91% of  
circulating hemoglobin
- Injuries found at laparotomy—  
shattered kidney, aortic and IVC  
perforations, spinal cord transection,  
injuries to all sections of bowel.
- Total transfusion 40 units over  
hospitalization
- Survived to discharge without organ  
dysfunction

# Terrorism

- World Trade Center and Pentagon
  - >3,000 deaths
  - Extremely lethal: killed to wounded ratio 5:1
- Oklahoma City
  - 167 deaths
  - More typical killed to wounded ratio of 1:5
- **Do you want to be in charge of the triage with our current blood supply**







# Dispersed Battlefield

- Evacuation times are related to mortality
- 20% mortality with evacuation in less than 2 hours
- 26% at 6 hours
- 32% at 24 hours *Bellamy, Mil Med 1984*



# Case Report

- 39 y/o female Jehovah's witness
  - 4 children
- Presented with abruptio placenta
  - HB 2gm/dl, HR>135, ST segment depressions, Fetal demise
- Transfused 18 units of PolyHeme and underwent hysterectomy
- Survived to discharge




# Hemoglobin Physiology






It's all about oxygen delivery

$$D_{O2} = CO * 1.34 (Hb * sat) + 0.003 * paO_2$$





# Deoxyhemoglobin

- Globin subunits are held in a tense configuration by electrostatic forces
- Low affinity for oxygen
- When oxygen binds a heme group the electrostatic forces weaken and a more relaxed configuration results


# Hill Coefficient

- Reflects cooperative effects of multiple oxygen binding
- Accounts for the sigmoid shape of the oxyhemoglobin dissociation curve
- Hill coefficient of adult RBC 2.7(2.4-2.9)




# Oxyhemoglobin dissociation Curve

- Factors that modify oxygen binding affinity
  - 2,3 DPG, carbon dioxide, hydrogen concentrations, and body temperature
    - Binding of 2,3 DPG between Beta chains of Hb stabilizes the tense conformation and reduces affinity for oxygen
    - Decreased 2,3 DPG increased oxygen affinity—curve is shifted left



What else does  
Hemoglobin do?



# History of hemoglobin- based oxygen carriers

# Hemolysates

- Sellards and Minot 1916-infused lysed RBCs to evaluate tolerance to hemolysis
- Amberson et. al 1933—First in vivo studies
  - Bovine hemolysate exchange transfusions in cats and dogs
  - Intact neurologic function after transfusion
  - Cats able to land on feet when dropped upside down
  - Animals died in 5 to 6 hours



# Hemolysates

- Amberson et al 1949
  - Transfused lysed RBCs into 14 patients
  - “Dissolved Hb transports oxygen much as it does when confined to the RBC
  - 1 of the 14 received 2300ml's(250g HB) secondary to postpartum hemorrhage
  - Died day 9 due to renal failure

# Human Hemolysates and Renal Dysfunction

- Brand and Miller in separate studies concluded that human hemolysates produced renal dysfunction
- Speculated cause
  - RBC membrane(stromal lipid)
- Moss 1973- evidence that stromal contamination provoked intravascular coagulation

# Stroma-free Hemoglobin

- Rabiner and De Venuto 1970's
  - Crystallization as a purification method
- Savitsky 1978
  - Infused 250 ml's of 99% stromal free hemoglobin into 8 healthy volunteers
    - Transient renal dysfunction
    - HTN
    - Abdominal pain

# Issues to Overcome

- Spontaneous dissociation into dimers and monomers
- Increased oxygen affinity,  $P_{50}$ -  
12<sub>mmHG</sub>
- Short intravascular retention
- Abnormal colloid osmotic pressure

# 1980's



# Approaches to Improve Oxygen Affinity

- Stabilize the Deoxy-HB
- Internal Cross link
- Recombinant DNA mutagenesis
- Use Non-human hemoglobin



# Approaches to Improve Vascular Retention

- Internal cross link of Hb tetramers
- DNA mutagenesis
- Surface conjugation
- Liposomal encapsulation
- Polymerization of HB tetramers

# First Attempt

- DCLHb—Diaspirin cross linked Hb



# Phase III Clinical Trial- 1990's

- Compared 1000ml DCLHb (1000g Hb) vs. Normal Saline as the initial resuscitation agent in patients presenting to the hospital in acute hemorrhagic shock
- Hypothesis—DCLHb administration during the first 2 hours of in hospital resuscitation could reduce the 28 day mortality

» Sloan, Koenigsburg, Gens, et al. JAMA 1999.



# WHY???


- Decreased oxygen delivery secondary to increased vascular resistance
- Macro and Micro vascular effects

# What?

- 1993 Hess et al. @ LAIR—DCLHb doubled SVR and PVR, associated drop in Cardiac Index (CI)
- DCLHb in critically ill patients reduced Norepinephrine requirements until @ 7.5 hrs PVR increased and CI, O<sub>2</sub> delivery decreased. Reah et al. *Crit Care Med* 1997.

# Mechanism

- Nitric Oxide (NO) Scavenging
- Remember the clover looking slide



# That Can't be it

- Oncotic effects—Vascular expansion decreases viscosity, Endothelial shear forces decrease, NO release is decreased.
- Pre-capillary arterioles are sensitive to hyperoxia. McCarthy, et al. *Biophys Chem* 2001.
- Endothelin release



# Remember

- It's all about oxygen delivery
- Oxygen supply and demand are coupled under standard operating conditions
- Macro and Micro circulatory effects are interconnected

# Present Status

- Currently successful oxygen carriers are polymerized
  - Increased intravascular retention
  - Reduced colloid osmotic pressure
  - Attenuation of vasoconstriction

# Current Lineup

Product	Manufacturer	Hb Source	Polymerization
Hemopure	Biopure Corp	Bovine	Glutaraldehyde
PolyHeme	Northfield Lab	Human	Glutaraldehyde


	Hemopur e	PolyHeme
P <sub>50</sub> (mm Hg)	38	29
Half-Life	19 hours	24 hours
Shelf-life @ 21 C	>2 years	> 6 weeks

# PolyHeme


- Case Reports of efficacy
- Safety established in healthy volunteers

# PolyHeme in initial Resuscitation


- 39 patients received 1(n=14), 2 (n=2), 3(n=15), or 6(n=8) units
- Patients were randomized to either PRBC's or PolyHeme.
- Map, Pap, CI, and PAWP were measured every 4 hours post infusion.
- No statistical differences were noted



A



B





# Our Study

- Randomized Placebo Controlled-  
16 swine
- GETA
- Underwent hemorrhage  
(1ml/kg/min) to remove 50% of  
EBV in 3 increments (10%, 30%,  
50%)

- Resuscitated with equal volume of HBOC201 or oncotically matched HSA
- Molecular Probes Fluorosphere microspheres used to determine regional blood flows
- Blood and tissue samples obtained 2 hours after final hemorrhage

# Baseline Stats



	Weight Kg	BSA cm <sup>2</sup>	Crystalloid ml	Exchange Volume ml
<b>HBOC201</b>	27.7 ± 1.8	83.1 ± 4.2	147 ± 83	981 ± 74
<b>5.9% HSA</b>	28.4 ± 2.3	83.7 ± 4.4	115 ± 72	998 ± 80

# Baseline Hemodynamics

		MAP mmHG	CV P mmHG	LVEDP mmHG	CI $\text{L} \cdot \text{min}^{-1} \cdot \text{m}^{-2}$	HR bpm	MPA P mmHG	PVRI $\text{dynes} \cdot \text{cm}^5 \cdot \text{m}^2$	SVRI $\text{dynes} \cdot \text{cm}^5 \cdot \text{m}^2$
<b>Baseline</b>	HBOC	$104 \pm 8$	$6 \pm 2$	$5 \pm 1$	$3.9 \pm 0.5$	$98 \pm 16$	$22 \pm 3$	$343 \pm 62$	$2110 \pm 493$
	5.9% HSA	$98 \pm 8$	$5 \pm 2$	$5 \pm 2$	$4.1 \pm 0.5$	$96 \pm 11$	$21 \pm 3$	$330 \pm 62$	$1991 \pm 391$

# 50% Exchange Hemodynamics


		MAP mmHG	CV P mmHG	LVEDP mmHG	CI $L \cdot \min^{-1} \cdot m^{-2}$	HR bpm	MPA P mmHG	PVRI $\text{dynes} \cdot \text{cm}^{-5} \cdot m^2$	SVRI $\text{dynes} \cdot \text{cm}^{-5} \cdot m^2$
50% Exchange	HBOC	98±1 3	5± 3	6± 3	3.6± 0.5	90± 14	<b>28± 4*</b>	<b>521±1 01*</b>	1891± 103
	5.9% HSA	<b>77±1 8*</b>	4± 2	3± 2	<b>5.2±0 .7*</b>	98± 14	20± 3	<b>250± 35*</b>	<b>1072±3 66*</b>




# Regional Bloodflow

Units (ml/100g/min)	Left Ventricle (LV) Baseline	Left Ventricle 50% Exchange	Frontal Cortex Baseline	Frontal Cortex 50% Exchange
Control	98.0 ± 9.0	100.2±10.6	47.7± 10.8	46.8 ± 10.4
HBOC201	110.1± 14.2	90.9 ± 13.1	51.2± 10.3	52.8 ± 10.3
5.9% HSA	117.8± 25.9	180.3± 46.7	48.7± 7.2	106.3± 14

## FRONTAL CORTEX



## SEPTUM





# Oxygen Delivery

		Arterial content ml/dl	Venous Content ml/dl	AV content Difference ml/dl	Arterial Oxygen Delivery ml/kg/min	Oxygen Consumpti on ml/kg/min
Baseline	HBOC201	12.7 ± 1.6	7.6 ± 1.8	5.1 ± 0.7	14.7 ± 1.9	5.9 ± 0.5
	5.9% HSA	12.3 ± 0.6	7.5 ± 0.8	4.7 ± 0.8	14.9 ± 0.8	5.7 ± 0.7
50% Exchange	HBOC201	11.7 ± 0.9	5.3 ± 0.7	<b>6.4 ± 1.2*</b>	12.6 ± 1.8	6.5 ± 0.6
	5.9% HSA	<b>6.7 ± 0.5*</b>	<b>2.7 ± 0.5*</b>	<b>4.0 ± 0.4*</b>	<b>10.6 ± 1.4*</b>	6.2 ± 0.8

# Discussion

- HBOC 201 was effective in restoring systemic pressure and oxygen delivery after acute incremental hemorrhage
- The pulmonary vasoconstrictive properties were significantly less than earlier compounds
- HBOC201 caused measurable alterations in systemic(minimal) and pulmonary(modest) pressures
- Pressure increases did not affect cardiac index or global oxygen delivery
- Flow studies and oxygen delivery/consumption data suggest physiologic coupling was not impaired by local vasoconstriction

Hemoglobin based oxygen  
carriers are on their way.

Get ready for a new tool.

# Questions?

Katz LM, et al: Resuscitation 2002; 54: 77-87

Malhotra AK, et al: J Trauma 2003; 54: 915-24

Sampson JB, et al: J Trauma 2003; 55: 747-54

Meisner FG, et al: Crit Care Med 2001; 29: 829-38

Standl TG, et al: Intensive Care Med 1997; 23:  
865-872

Gould SA, et al: J Trauma 1997; 43:325-32

De Venuto, et al: Transfusion 1977;17:555-6.

# References Cont.

- Sloan, et al: JAMA 1999;282:1847-64.
- Hess, et al: J Appl Physiol 1993;74: 1769-78.
- Lee, et al: J Appl Physiol 1995; 79: 236-42.
- Koch, et al: Shock 1994; 1: 146-52.
- Rohifs, et al: J Biol Chem 1998; 273: 12128-34.
- Bellamy RF: Mil Med; 149: 55-62.